Boothbay Fund Management LLC Takes Position in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA)

Boothbay Fund Management LLC bought a new position in shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 2,587,046 shares of the company’s stock, valued at approximately $1,811,000. Boothbay Fund Management LLC owned approximately 0.06% of Verrica Pharmaceuticals as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in VRCA. Heights Capital Management Inc. acquired a new position in shares of Verrica Pharmaceuticals in the 4th quarter valued at $246,000. Renaissance Technologies LLC increased its stake in Verrica Pharmaceuticals by 57.7% in the fourth quarter. Renaissance Technologies LLC now owns 233,300 shares of the company’s stock valued at $163,000 after acquiring an additional 85,336 shares during the period. Invesco Ltd. acquired a new position in Verrica Pharmaceuticals in the fourth quarter worth about $32,000. Geode Capital Management LLC lifted its stake in Verrica Pharmaceuticals by 4.8% during the fourth quarter. Geode Capital Management LLC now owns 477,269 shares of the company’s stock worth $334,000 after purchasing an additional 21,789 shares during the period. Finally, Rhumbline Advisers boosted its holdings in Verrica Pharmaceuticals by 975.2% during the fourth quarter. Rhumbline Advisers now owns 266,093 shares of the company’s stock valued at $186,000 after purchasing an additional 241,344 shares in the last quarter. 42.45% of the stock is currently owned by institutional investors.

Verrica Pharmaceuticals Trading Down 5.1 %

NASDAQ:VRCA opened at $0.46 on Tuesday. The stock has a market capitalization of $42.91 million, a P/E ratio of -0.25 and a beta of 1.68. Verrica Pharmaceuticals Inc. has a 1 year low of $0.38 and a 1 year high of $11.41. The firm has a 50 day moving average of $0.55 and a 200-day moving average of $0.79.

Verrica Pharmaceuticals (NASDAQ:VRCA) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.01. Verrica Pharmaceuticals had a negative return on equity of 591.84% and a negative net margin of 625.06%. The firm had revenue of $0.34 million during the quarter, compared to the consensus estimate of $1.30 million. As a group, analysts forecast that Verrica Pharmaceuticals Inc. will post -1.46 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on VRCA. HC Wainwright reissued a “neutral” rating on shares of Verrica Pharmaceuticals in a report on Tuesday, April 8th. Needham & Company LLC reiterated a “hold” rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, April 9th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $9.50.

Verrica Pharmaceuticals Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.